Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 1, 1996
Bifunctional NHS-BAT ester for antibody conjugation and stable technetium-99m labeling: conjugation chemistry, immunoreactivity and kit formulationM Eisenhut, W D Lehmann, W Becker, et al.
Cancer Research|February 15, 1997
Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancerB Stockmeyer, T Valerius, R Repp, et al.
The Journal of Urology|January 17, 2002
Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?H Stadick, B Stockmeyer, R Kühn, et al.
Blood|May 1, 1996
HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factorD Elsässer, T Valerius, R Repp, et al.
Cancer Research|July 29, 1998
Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cellsD Würflein, M Dechant, B Stockmeyer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 9, 2000
Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapyB Stockmeyer, M Dechant, M van Egmond, et al.
Blood|December 31, 1997
FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapyT Valerius, B Stockmeyer, A B van Spriel, et al.
Leukemia|June 5, 2012
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cellsP Glorius, A Baerenwaldt, C Kellner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 21, 1998
Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodiesI A Heijnen, L J Rijks, A Schiel, et al.
British Journal of Cancer|December 17, 2003
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancerR Repp, H H van Ojik, T Valerius, et al.
Pageof 5